Compare Synchrony Financial (SYF) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs BIO-TECHNE Corp — how do they compare? Synchrony Financial trades at $78.71 (market cap $25.58B), while BIO-TECHNE Corp trades at $72.3 (market cap $11.34B). The key difference: Synchrony Financial is far larger — about 2.3× BIO-TECHNE Corp's market cap, and Synchrony Financial pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| SYF | TECH | |
|---|---|---|
Market Cap | $25.58B | $11.34B |
Sector | Financials | Health |
52-Week High | $88.47 | $72.48 |
52-Week Low | $63.78 | $43.31 |
Dividend Yield | 1.73% | 0.44% |
Enterprise Value | — | $11.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with strong technical support at $77-79 and bullish moving averages. The stock shows robust fundamentals with a low P/E of 8.2, ROE of 22.23%, and consistent earnings beats in recent quarters. Recent positive catalysts include a strategic partnership with OpenAI to enhance AI-driven commerce capabilities and the appointment of a Chief AI Officer, positioning the company for growth in digital financial services.
SYF presents a compelling value opportunity with analyst consensus pointing to 11% upside to the $87.33 price target. Strong institutional support and zero sell ratings reflect confidence, though risks include consumer credit deterioration and potential economic headwinds affecting payment volumes. The company's aggressive buyback program and stable credit trends support the bullish case.
Bio-Techne Corporation (TECH) trades at $72.31, down 0.17% on the day, with a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, while valuation ratios like P/E of 62.44 and P/S of 9.36 appear elevated. Recent Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, and the company declared a $0.08 dividend payable in August 2026. Revenue trends are stable, but net income margin declined to 14.97% in 2025 from 25.09% in 2023, indicating profitability pressure.
Outlook is cautiously optimistic amid a pending acquisition by Merck KGaA at $73.00 per share, near the current price. Risks include high valuation, earnings volatility, and shareholder litigation scrutiny. Analysts are split with 46% buy ratings but no sells, and a consensus target of $71.86 suggests limited upside. Institutional interest is strong, with BlackRock adding shares in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
